Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2025 04:17 ET | Source: Oculis Holding AG

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to...
October 14, 2025 16:05 ET | Source: Oculis Holding AG

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The attached two notifications relate to the exercise of vested stock options to purchase ordinary shares previously granted to a director of the...
October 14, 2025 04:00 ET | Source: Oculis Holding AG

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and...
October 14, 2025 04:00 ET | Source: Oculis Holding AG

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and...
October 08, 2025 16:05 ET | Source: Oculis Holding AG

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

ZUG, Switzerland, Oct. 08, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment ...
October 06, 2025 04:07 ET | Source: Oculis Holding AG

Oculis hrindir af stað skráningarrannsóknum á Privosegtor við bráðri sjóntaugabólgu, sem gæti orðið fyrsta taugaverndandi meðferð sinnar tegundar

ZUG, Sviss, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Árangursríkur fundur með Matvæla- og lyfjastofnun Bandaríkjanna (FDA) skapar möguleika á að hefja skráningarrannsóknir á Privosegtor sem meðferð við...
October 06, 2025 04:07 ET | Source: Oculis Holding AG

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior...
October 06, 2025 04:07 ET | Source: Oculis Holding AG

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch...
September 26, 2025 16:05 ET | Source: Oculis Holding AG

Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities

ZUG, Switzerland, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule...
September 22, 2025 04:00 ET | Source: Oculis Holding AG

Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS

ZUG, Switzerland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and...